U.S., April 12 -- ClinicalTrials.gov registry received information related to the study (NCT06923072) titled 'Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement' on April 10.
Brief Summary: Background:
Kohlmeier-Degos (KD) is a rare disease that causes inflammation and blood clots, leading to blockages in small blood vessels. These blockages can result in K-D lesions throughout the body, affecting the skin, lungs, heart, spinal cord, and brain. KD can be fatal. No treatment exists for this disease.
Objective:
To test a study drug (baricitinib) in people with brain and spine lesions caused by KD disease. Baricitinib is FDA approved to treat other disorders but has not yet been tried in peopl...